Cidara Therapeutics Operating Income 2014-2022 | CDTX

Cidara Therapeutics operating income from 2014 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Cidara Therapeutics Annual Operating Income
(Millions of US $)
2021 $-42
2020 $-72
2019 $-42
2018 $-63
2017 $-56
2016 $-48
2015 $-32
2014 $-12
2013 $-1
Cidara Therapeutics Quarterly Operating Income
(Millions of US $)
2022-03-31 $-18
2021-12-31 $-17
2021-09-30 $-18
2021-06-30 $11
2021-03-31 $-18
2020-12-31 $-22
2020-09-30 $-18
2020-06-30 $-18
2020-03-31 $-15
2019-12-31 $-14
2019-09-30 $3
2019-06-30 $-14
2019-03-31 $-16
2018-12-31 $-17
2018-09-30 $-15
2018-06-30 $-15
2018-03-31 $-17
2017-12-31 $-13
2017-09-30 $-12
2017-06-30 $-17
2017-03-31 $-13
2016-12-31 $-14
2016-09-30 $-12
2016-06-30 $-12
2016-03-31 $-10
2015-12-31 $-10
2015-09-30 $-9
2015-06-30 $-6
2015-03-31 $-7
2014-12-31 $-5
2014-09-30 $-3
2014-06-30 $-3
2014-03-31 $-1
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.032B $0.050B
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00